New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
08:15 EDTMACKMerrimack identifies heregulin as patient response biomarker for MM-121
Merrimack Pharmaceuticals reported that expression of heregulin, the principal ligand that binds to and activates the ErbB3 receptor, is associated with poor response to standard of care therapy for patients with platinum-resistant ovarian cancer, ER/PR+ HER2- breast cancer and EGFR wild-type non-small cell lung cancer. Heregulin-driven drug resistance pathways were found to be active in approximately 30-50% of patients tested. Results from three Phase 2 studies further showed that patients with heregulin-positive tumors experienced a statistically significant reduction in their risk of progression when they received a combination of MM-121 with their standard of care therapy as compared to patients who received the standard of care therapy alone. MM-121 is specifically designed to block heregulin binding to ErbB3. Top line data from these trials had previously been released. Detailed biomarker data for all three studies were presented at the American Society of Clinical Oncology Annual Meeting, May 30-June 3. Akos Czibere, MD, PhD, Senior Medical Director at Merrimack, said, "We look forward to advancing MM-121 into definitive studies that will allow us to prospectively screen patients for heregulin."
News For MACK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
18:28 EDTMACKOn The Fly: After Hours Movers
Subscribe for More Information
17:54 EDTMACKMerrimack Chief Scientific Officer Ulrik Nielsen resigns
Subscribe for More Information
January 20, 2015
08:16 EDTMACKMerrimack data of Phase 3 MM-398 NAPOLI-1 study supports development programs
Merrimack Pharmaceuticals (MACK) announced that additional analyses were presented on January 16, 2015 from the Phase 3 NAPOLI-1 study of MM-398, also known as nal-IRI, in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy. Merrimack and Baxter International's (BAX) biopharmaceutical business are collaborating on the development and commercialization of MM-398 outside of the United States and Taiwan. PharmaEngine holds the rights to commercialize MM-398 in Taiwan. Additionally, Merrimack presented preclinical and clinical data from studies of its investigational agents MM-141 and MM-151 in pancreatic and colorectal cancer, respectively. An investigator-sponsored study of MM-398 in colorectal cancer was also presented. The extended analyses for the global NAPOLI-1 Phase 3 trial presented at ASCO GI support the robustness of the overall survival benefit of MM-398 in combination with 5-fluorouracil, or 5-FU, and leucovorin presented in June 2014, at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer, or ESMO GI. The primary analysis, presented at ESMO GI, demonstrated a statistically significant advantage in overall survival with an unstratified hazard ratio of 0.67, and a median of 6.1 months for the combination of MM-398 plus 5-FU and leucovorin compared to 4.2 months in the control arm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use